
Opinion|Videos|June 9, 2025
Closing Thoughts About IgA Nephropathy Treatment
Panelists discuss how the management of immunoglobulin A (IgA) nephropathy is undergoing a transformative shift from symptom control to targeted disease modification, with emerging therapies offering new hope for patients while requiring thoughtful integration into clinical practice and health care systems.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Flow Cytometry Tracks CAR T-Cell Therapy Persistence in Aggressive LBCL
2
Newly Identified RTEL1 Variant Could Broaden Genetic Landscape of Familial PF
3
Inside the VA’s Hub-and-Spoke Model for Multiple Sclerosis Care: Rebecca Spain, MD
4
2025 Hypertension Guideline Updates Presented at AHA Scientific Sessions
5
















































